This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

CT-011 MAb in DLBCL Patients Following ASCT

This study has been completed.
Information provided by (Responsible Party):
CureTech Ltd Identifier:
First received: September 19, 2007
Last updated: September 8, 2014
Last verified: September 2014
Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease. Although many people are cured of their lymphoma with this therapy, the disease comes back in a certain proportion of patients. The purpose of this study is to test the safety and effectiveness of the monoclonal antibody, CT-011, in patients with DLBCL who have received autologous peripheral blood stem cell transplantation. All final eligible patients will receive an IV infusion of CT-011 on Day 1 (30 to 90 days post autologous PBSCT). Treatment will be repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85. Follow-up for safety and clinical outcome will be conducted throughout the study till 18 months post autologous PBSCT. Approximately 70 patients will participate in this study.

Condition Intervention Phase
Lymphoma, Large Cell, Diffuse Lymphoma, Mixed Cell, Diffuse Primary Mediastinal Large B-Cell Lymphoma Drug: CT-011 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by CureTech Ltd:

Primary Outcome Measures:
  • Progression-free Survival [ Time Frame: 16 months following the first CT-011 administration (approximately 18 months following autologous PBSCT). ]
    PFS (progression-free survival ) will be determined at the eligible patient populations

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: within 16 months following the first CT-011 treatment (18 months following autologous PBSCT). ]

Enrollment: 72
Study Start Date: October 2007
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CT-011
The monoclonal antibody termed CT-011 (currently, pidilizumab).
Drug: CT-011
IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
Other Name: Pidilizumab


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient's age is 18 years or older, both genders.
  2. Confirmed Diffuse Large B-cell Lymphoma, transformed follicular lymphoma, diffuse mixed cell lymphoma or primary mediastinal large cell lymphoma with B-cell lineage.
  3. The lymphoma is chemosensitive.
  4. The lymphoma did not progress since pre-transplant chemotherapy.
  5. ECOG performance status 0-1.

Exclusion Criteria:

  1. Serious other illness.
  2. Active autoimmune disease.
  3. Type 1 diabetes.
  4. Known immune deficiency.
  5. Clinical evidence of primary or secondary brain or spinal cord involvement by lymphoma.
  6. Active bacterial, fungal, or viral infection.
  7. Positive HIV, Hepatitis B surface antigen plus viremia, or Hepatitis C antibody plus viremia.
  8. Pregnant or nursing (positive pregnancy test).
  9. Other concurrent clinical study or investigational therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00532259

  Show 27 Study Locations
Sponsors and Collaborators
CureTech Ltd
Principal Investigator: Leo I Gordon, MD Northwestern University Feinberg School of Medicine
Principal Investigator: Arnon Nagler, MD Chaim Sheba Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: CureTech Ltd Identifier: NCT00532259     History of Changes
Other Study ID Numbers: CT-2007-01
Study First Received: September 19, 2007
Results First Received: September 22, 2013
Last Updated: September 8, 2014

Keywords provided by CureTech Ltd:
Lymphoma, Large B-Cell, Diffuse
Transformed Follicular Lymphoma
Stem cell transplantation

Additional relevant MeSH terms:
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on August 18, 2017